Low-dose continuous intravenous infusion of 5-fluorouracil for metastatic breast cancer

Annals of Oncology

Volumn 7, Issue 8, 1996, Pages 807-813

  Regazzoni, S ^b   Pesce, G ^d   Marini, G ^a   Cavalli, F ^a,b,c,d,e   Goldhirsch, A ^a,b,c,d,e,f  

^a Ospedale Civico   (Switzerland)

^b Ospedale Beata Vergine   (Switzerland)

^c OSPEDALE SAN GIOVANNI   (Switzerland)

^d Ospedale Italiano   (Switzerland)

^e Ospedale La Carita   (Switzerland)

^f Ospedale Civico Lugano   (Switzerland)

Author keywords

5 fluorouracil; Advanced breast cancer; Chemotherapy; Financial costs; Infusion; Low dose continuous; Palliative; Quality of life; Therapy

Indexed keywords

DOXORUBICIN; FLUOROURACIL;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; BREAST CANCER; CLINICAL TRIAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MUCOSA INFLAMMATION; NAUSEA; PALLIATIVE THERAPY; PRIORITY JOURNAL; VOMITING;

EID: 0029860378     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/oxfordjournals.annonc.a010759     Document Type: Article

References (33)

1. Cooper RG. Combination chemotherapy in hormone-resistant breast cancer. Proc Am Assoc Cancer Res 1969; 10: 15.
2. Smalley R, Carpenter J, Bartolucci A et al. A comparison of cyclophosphamide, adriamycin, 5-fluorouracil (CAF) and cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, prednisone (CMFVP) in patients with metastatic breast cancer. Cancer 1977; 40: 625-32.
3. Konits P, Aisner J, VanEcho D et al. Mitomycin C and vinblastine chemotherapy for advanced breast cancer. Cancer 1981; 48: 1295-8.
4. Seidman AD, Tiersten A, Hudis C et al. Phase II trial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy for metastatic breast cancer. J Clin Oncol 1995; 13: 2575-81.
5. Hudis CA, Seidman AD, Crown JPA et al. Phase II and pharmacologic study of docetaxel for metastatic breast cancer. J Clin Oncol 1996; 14: 58-65.
6. Jones S, Winer E, Vogel G et al. A multicenter, randomized trial of navelbine vs. i.v. alkeran in patients with anthracycline-refractory advanced breast cancer. Proc Am Soc Clin Oncol 1994; 13: A216.
7. Cocconi G, Bisagni G, Bacchi M et al. Cisplatin and etoposide as first-line chemotherapy for metastatic breast carcinoma: A prospective randomized trial of the Italian oncology group for clinical research. J Clin Oncol 1991; 9: 664-70.
8. Ansfield F, Koltz F, Nealon T et al. A phase 3 study comparing the clinical utility of four regimens of 5-fluorouracil. Cancer 39: 1977; 34-40.
9. Pinedo HM, Peters GFJ. Fluorouracil: Biochemistry and pharmacology. J Clin Oncol 1988; 6: 1653-64.
10. Cameron DA, Gabra H, Leonard RCF. Continuous 5-fluorouracil in the treatment of breast cancer. Br J Cancer 1994; 70: 120-4.
11. Ng JSY, Cameron DA, Leonard RCF. Infusional 5-fluorouracil in breast cancer. Cancer Treat Rew 1994; 20: 357-64.
12. Lemon HM. Reduction of 5-fluorouracil toxicity in man with retention of anticancer effects by prolonged intravenous administration in 5% dextrose. Cancer Chemother Rep 1960; 8: 97-101.
13. Lokin J, Bothe A Jr, Fine N et al. Phase I study of protracted venous infusion of 5-fluorouracil. Cancer 1981; 48: 2565-8.
14. Huan S, Pazdur R, Singhakowinta A et al. Low-dose continuous infusion 5-fluorouracil evaluation in advanced breast carcinoma. Cancer 1989; 63: 419-22.
15. Hatfield AK, Johnson PA, Egner JR, Long CA. Continuous 5-fluorouracil infusion in the treatment of far advanced metastatic breast carcinoma. Proc Annu Meet Am Soc Clin Oncol 1989; 8: A132.
16. Hansen R, Quebbeman E, Beatty P et al. Continuous 5-fluorouracil infusion in refractory carcinoma of the breast. Breast Cancer Res Treat 1987; 10: 145-9.
17. Jabboury K, Holmes FA, Hortobagyi G. 5-Fluorouracil rechal-lenge by protracted infusion in refractory breast cancer. Cancer 1989; 64: 793-7.
18. Berlie J, Meeus L, Meyer C et al. Protracted continuous infusion of 5-fluorouracil among breast cancer patients. Proc Annu Meet Am Soc Clin Oncol 1990; 9: A153.
19. Chang AY, Most C, Pandya KJ. Continuous intravenous infusion of 5-fluorouracil in the treatment of refractory breast cancer. Am J Clin Oncol 1989; 12: 453-5.
20. Dorr RT, Von Hoff DD. Drug Monographs. In Dorr RT, von Hoff DD (eds): 5-Fluorouracil in Cancer Chemotherapy Handbook. 2nd edition. Norwalk/Connecticut: Appleton and Lange 1994; 500-15.
21. Lokich JJ, Ahlgren JD, Gullo JJ et al. A prospective randomized comparison of continuous infusion fluorouracil with conventional bolus schedule in metastatic colorectal carcinoma: A Mid-Atlantic Oncology Program study. J Clin Oncol 1989; 7: 425-32.
22. Smith IE, Walsh G, Jones A et al. High complete remission rates with primary neoadjuvant infusional chemotherapy for large early breast cancer. J Clin Oncol 1995; 13: 424-9.
23. Bonnefoi H, Smith IE, Brien MER et al. Phase II study of infusional 5-fluorouracil with epirubicin and carboplatin (instead of cisplatin) in patients with metastatic/locally advanced breast cancer (infusional ECarboF): A very active and well tolerated outpatient regimen. Br J Cancer 1996; 73: 391-6.
24. Formenti SC, Lenz J, Dunnington G et al. Initial p53 status as potential predictor for pathological response to the combination of 5-FU and radiotherapy in locally advanced breast cancer. Proc Annu Meet Am Soc Clin Oncol 1996; 15: A174.
25. WHO Handbook for Reporting Results of Cancer treatment. WHO Offset Publication No. 48. Geneva: World Health Organization 1979.
26. Brunner KW, Sonntag RW, Martz G et al. A controlled study in the use of combined drug therapy for metastatic breast cancer. Cancer 1975; 36: 1208-19.
27. Kaplan IL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-81.
28. Simon R. Confidence intervals for reporting results of clinical trials. Ann Intern Med 1986; 105: 429-35.
29. Halevy A, Leonov Y, Lewinsohn G et al. Thrombosis of superior vena cava during total parenteral nutrition, managed successfully with low dose streptokinase. Intensive Care Med 1988; 14: 72-3.
30. Gregory WM, Smith P, Richards MA et al. Chemotherapy of advanced breast cancer: Outcome and prognostic factors. Br J Cancer 1993; 68: 988-95.
31. Hochster H, Wasserheit C, Speyer J. Cardiotoxicity and cardio-protection during chemotherapy. Curr Opin Oncol 1995.
32. Akhtar S, Salim K, Bano Z. Symptomatic cardiotoxicity with high-dose 5-fluorouracil infusion: A prospective study. Oncology 1993; 50: 441-4.
33. Coates A, Gebski V, Stat M et al. Improving the quality of life during chemotherapy for advanced breast cancer: A comparison of intermittent and continuous treatment strategies. N Engl J Med 1987; 317: 1490-5.